Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333638 | 0.98 | LMNA (0.50) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL5384819 | 0.98 | LMNA (0.50) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL6880705 | 0.92 | USP2 (0.41) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL7249850 | 0.84 | USP2 (0.33) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL7254431 | 0.81 | LMNA (0.31) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL7248650 | 0.81 | LMNA (0.31) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL7255438 | 0.81 | APP (0.32) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL7174675 | 0.80 | USP2 (0.37) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL7423794 | 0.80 | CYP1A2 (0.46) | LMNABLMUSP2ALDH1A1CYP1A2 | |
| SCHEMBL7423791 | 0.80 | CYP1A2 (0.46) | LMNABLMUSP2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1475371-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (= GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2004-11-10 | — | — | EP | claimed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | claimed |
| CN-1495160-A | I-substituted-1-aminomethyl-cycloalkane derivative (gabapentin analogs), its preparation and application for curing neuropathy | ��ʲ | 2004-05-12 | — | — | CN | claimed |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | DOOLEY DAVID JAMES (US) | 2004-01-08 | — | — | US | claimed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
| JP-2002508362-A | — | — | 2002-03-19 | — | — | JP | claimed |
| CN-1279674-A | 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders | WARNER LAMBERT CO (US) | 2001-01-10 | — | — | CN | claimed |
| EP-1047678-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2000-11-02 | — | — | EP | claimed |
| WO-1999031075-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
| CN-101283995-A | Different pharmaceutical uses alpha2delta ligands | WARNER LAMBERT CO (US) | 2008-10-15 | — | — | CN | disclosed |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| CN-1279674-A | 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders | WARNER LAMBERT CO (US) | 2001-01-10 | — | — | CN | disclosed |
| EP-0133318-B1 | CYCLOALIPHATIC AMINOSULPHONIC-ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS FOR COMBATING HEART AND VASCULAR DISEASES | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1987-01-07 | — | — | EP | disclosed |
| US-4587263-A | CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1986-05-06 | — | — | US | disclosed |
| EP-0133318-A1 | Cycloaliphatic aminosulphonic-acid derivatives, process for their production and pharmaceutical preparations for combating heart and vascular diseases | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | LMNA 2350/4885BLM 3962/4885USP2 4327/4885 |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | LMNA 2350/4885BLM 3962/4885USP2 4327/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | LMNA 406/4885BLM 2270/4885USP2 1071/4885 |
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | LMNA 2350/4885BLM 3962/4885USP2 4327/4885 |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | LMNA 2350/4885BLM 3962/4885USP2 4327/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | LMNA 406/4885BLM 2270/4885USP2 1071/4885 |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | GABRB2, GABBR1, GABBR2 | LMNA 4731/4885BLM 4687/4885USP2 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.